“…Factors predictive of an increased risk of disease progression in keratoconus include young age (r35 years), steep keratometry, high astigmatism, reduced CDVA (irregular astigmatism), ethnicity other than white European, and documented progression in the contralateral eye. [37][38][39] These risk factors for disease progression are often present at presentation, and may be compounded if further disease progression is allowed to occur. Based on this, the proven efficacy of CXL, 14,18,19,21,22 the higher risk of CXL-related visual loss aged 435 years, 22 and the relative safety of transepithelial treatment, 33,34 we believe that there is a rational argument for transepithelial CXL at presentation for patients r35 years of age with keratometric stage II disease (Figures 2 and 3).…”